Page 89 - Clinical Development News Today

The UK startup Intelligent OMICS (Intellomx) has launched a collaboration with Johnson & Johnson’s pharmaceutical company Janssen to use artificial intelligence (AI) to discover drug targets for the treatment of blood cancer.

Less than a month after the U.S. Food and Drug Administration (FDA) gave its antidepressant drug zuranolone (Zurzuvae) a mixed welcome, Sage Therapeutics has launched plans to reorganize its operations by refocusing its drug development efforts and laying off 40% of its workforce.

Imugene Ltd (ASX:IMU, OTC:IUGNF) has brought on board Dr John Byon as senior vice president of Clinical Development to further the company’s development of...

Successfully closed upsized IPO, raising $88 million in gross proceeds to continue advancing pipeline of Selected TIL Therapy programsCash position expected to fund operations into second quarter of...

Potential growth catalysts include planned 4Q 2023 launch of ZURZUVAE and expected data read-outs for SAGE-718 and SAGE-324 in 2024 Approximately 40% workforce reduction supports focus on agile...

More people are talking about mental illness than ever before. However, despite increased awareness, it remains one of the most neglected areas of public health globally, with research and quality of care lagging behind physical health conditions.

By Ian Walker Shares of Ovoca Bio fell 82% in early trade after the company said that a study of Orenetide didn't show any significant improvement in female...

/PRNewswire/ -- Indiana Center for Recovery has been recognized on Newsweeks list of Americas Best Addiction Treatment Centers for 2023. This prestigious...

Ovoca Bio PLC shares plummeted on Thursday, after it said that a study into Orenetide did not show statistically significant superiority versus placebo. Shares in Ovoca were down 43% to 8.00 pence...

Stock prices in London closed mixed on Thursday, after news that a key US inflation reading came in in line with market expectations. The FTSE 100 index closed down 34.54 points, 0.5%, at 7,439.13....